<DOC>
	<DOCNO>NCT02719990</DOCNO>
	<brief_summary>Open-label extension study evaluate safety long-term twice-monthly administration somavaratan adult Growth Hormone Deficiency ( GHD ) .</brief_summary>
	<brief_title>Open-label Extension Study Evaluate Safety Long-term Twice-monthly Administration Somavaratan AGHD</brief_title>
	<detailed_description>An open-label extension study evaluate safety long-term twice-monthly administration somavaratan adult Growth Hormone Deficiency ( GHD ) . This multicenter study open subject complete Versartis adult GHD study well approximately 40 new somavaratan naïve subject ( either rhGH treatment naïve currently receive daily rhGH therapy ) . All subject receive twice-monthly ( every 15 day ± 2 day ) subcutaneous ( SC ) somavaratan . Doses titrate subject 's individual IGF-I response base IGF-I level 7 day post-dose maintenance dose achieve . Subjects receive somavaratan previous somavaratan study dose decrease half ( minimum dose 20 mg , 40 mg woman estrogen , round near even number ) titrate per Dose Titration Plan . New subject enrol study assign one two cohort base sensitivity rhGH titrate per Dose Titration Plan .</detailed_description>
	<mesh_term>Endocrine System Diseases</mesh_term>
	<mesh_term>Dwarfism , Pituitary</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Female subject childbearing potential must negative pregnancy test use appropriate contraceptive method Documented GHD adulthood Subjects naive somavaratan must IGF1 SDS value ≤ 0 Screening Subjects take hormone replacement therapy must stable course treatment least 3 month Underlying disorder responsible subject 's GHD must clinically stable least 6 month Subjects receive daily rhGH injection must washout ≥ 14 day BMI ( kg/m2 ) 18.0 40.0 Untreated adrenal insufficiency Recently diagnose thyroid dysfunction treat stable therapy least 3 month Currently take antiinflammatory dose glucocorticoid could potentially compromise safety efficacy assessment Currently take GHRH IGFI product Current significant cardiovascular disease , heart insufficiency New York Heart Association ( NYHA ) class &gt; 2 Current significant disease think increase risk receive growth hormone confound assessment study outcomes History diabetes mellitus inadequate glucose control Current drug alcohol abuse Current HIV waste syndrome ( HIV test require ) History malignancy adulthood ( subject history childhood malignancy subsequently treat rhGH childhood remain GHD adulthood may enrol ) Women pregnant breastfeeding Treatment investigational drug somavaratan within 30 day prior Screening A significant abnormality Screening laboratory result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>VRS-317</keyword>
	<keyword>Long Acting Growth Hormone</keyword>
	<keyword>Versartis</keyword>
	<keyword>somavaratan</keyword>
	<keyword>Growth Hormone Deficiency</keyword>
	<keyword>Adult Growth Hormone Deficiency</keyword>
	<keyword>AGHD</keyword>
	<keyword>Growth Hormone Replacement</keyword>
	<keyword>Growth Hormone Replacement Therapy</keyword>
	<keyword>XTEN</keyword>
</DOC>